SAN DIEGO--(BUSINESS WIRE)--April 27, 2004-- Signet Operates 16 Multi-Modality Diagnostic Imaging Centers Throughout Florida and Puerto Rico
Molecular Imaging Corporation (“MLRI” or the “Company”) (OTC BB: MLRI), a leading provider of Molecular Imaging Services to healthcare entities in the U.S., today announced that it has entered into a multi-year agreement with Signet Diagnostic Imaging Services Group, LLC (“Signet”) to provide PET scanning services using a state of the art PET/CT unit which initially will service six of Signet’s diagnostic imaging centers located throughout the state of Florida.
“With Molecular’s expertise in PET imaging services technology, combined with Signet’s core expertise in the operation and management of diagnostic imaging modalities, we are confident that our payors and physician referral base will immediately see a tremendous benefit to their patients and members from the implementation of this mobile service,” said Jamshid Keynejad, President of Signet. “It is our intention to use the mobile means of service delivery to respond to our payors’ request to expand our excellent patient care throughout the State of Florida,” Mr. Keynejad went on to say.
“As patients and their doctors become more acquainted with PET/CT technology, and its potential for improving patient care, the demand for access to services will escalate. Signet has recognized this emerging trend and is being proactive in addressing the needs of its patients now,” said Peter S. Conti, M.D., Ph.D., Chairman of the Medical Advisory Board for Molecular Imaging Corporation and Vice President-Elect of The Society of Nuclear Medicine.
“Signet is a well respected provider of diagnostic imaging services, operating 16 full-service facilities throughout Florida and Puerto Rico. Their decision to utilize our services is in keeping with their desire to provide their payors beneficiaries and physicians with the most effective diagnostic imaging technology available in the marketplace. We look forward to growing our relationship with Signet and are pleased that MIC was selected as the vendor of choice,” said Paul Crowe, President of Molecular Imaging Corporation.
About Molecular Imaging Corporation
Molecular Imaging Corporation is a leading national service provider of Positron Emission Tomography (“PET”) diagnostic imaging services. PET is a 3-Dimensional Full Body molecular imaging procedure used to diagnose stage and assess treatment outcomes for many cancers, cardiovascular disease and neurological disorders. The Company operates both mobile and permanent (fixed) PET imaging technologies for hospitals, diagnostic imaging centers and physician group practices offices across the U.S. The Company’s clinical web site, www.PETadvances.com addresses questions about the various cancers and how molecular imaging can assist and benefit physicians and their patients. The Company’s commercial web site, (www.molecularimagingcorp.com) addresses questions about our commercial services and investor relations.
About Signet Diagnostic Imaging Services Group, LLC
Signet Diagnostic Imaging Services Group, LLC (Signet) is a dynamic, rapidly growing company that operates multi-modality diagnostic imaging centers throughout the State of Florida and the Commonwealth of Puerto Rico. Although the name Signet is relatively new on the diagnostic imaging scene, the company itself is actually the successor to a long line of companies who have served the medical imaging needs of the residents of Florida and Puerto Rico for many years. Signet currently operates 16 multi-modality centers offering the full spectrum of diagnostic imaging services, from MRI and CT to x-ray, nuclear medicine and ultrasound.
Certain statements contained in this press release are “forward-looking statements” within the meaning of applicable federal securities laws, including, without limitation, anything relating or referring to future financial results and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by the company with the Securities and Exchange Commission. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward the forward-looking statements contained herein. The companies undertake no obligation to publicly release statements made to reflect events or circumstances after the date hereof.
Contacts
Molecular Imaging Corporation Debbie Zeineddine, 619-226-6738 dzeineddine@molecularimagingcorp.com or
Crosslink Financial Communications Terry McGovern/Bill Arnold, 415-924-9900 tmcgovern@crosslinkfinancial.com